TransMedics Group Inc (TMDX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.20B
Last updated: Nov 17, 2026 at 4:30 PM ET
TransMedics Group Inc (TMDX) Statistics
TransMedics Group (TMDX) has a market cap of $3.20B and an enterprise value of $3.57B. Revenue grew 28.48% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 11.50% above the market cap, as debt exceeds cash.
| Market Cap | $3.20B |
|---|---|
| Enterprise Value | $3.57B |
| Latest price (Nov 17, 2026) | $93.91 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.5x and 5.9x. Its year-end P/E ranged from 52.2x to 986.6x from 2023 to 2025.
| P/E Ratio | 72.2x |
|---|---|
| Forward P/E | 55.0x |
| P/S Ratio | 4.5x |
| Forward P/S | 4.2x |
| P/B Ratio | 5.9x |
| P/TBV Ratio | 6.1x |
| P/FCF Ratio | 72.9x |
| P/OCF Ratio | 28.5x |
| PEG Ratio | 2.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 26.1x EBITDA and 81.1x free cash flow.
| EV / Earnings | 24.7x |
|---|---|
| EV / Sales | 4.9x |
| EV / EBITDA | 26.1x |
| EV / EBIT | 36.2x |
| EV / FCF | 81.1x |
Price Statistics
The stock is down 18.35% over 52 weeks and trades 16.75% above its 50-day average.
| Beta (1Y) | 1.20 |
|---|---|
| 52-Week Change | -18.35% |
| 1-Month Change | +31.16% |
| 3-Month Change | -0.06% |
| 6-Month Change | +42.01% |
| 5-Year Change | +140.58% |
| Total Return (1Y) | -18.35% |
| Total Return (3Y CAGR) | +10.98% |
| Total Return (5Y CAGR) | +32.52% |
| Return vs SPY (1Y) | -31.34% |
| Max Drawdown (1Y) | -58.76% |
| Max Drawdown (3Y) | -67.79% |
| Sharpe Ratio (1Y) | -0.35 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $80.44 |
| 200-Day Average | $91.22 |
| 52-Week Range | $60.10 to $156.00 |
| RSI (14 Days) | 68.3 |
| Average Volume (20 Days) | 1.22M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.53x current liabilities, and total debt is 1.56x shareholder equity.
| Current Ratio | 4.53x |
|---|---|
| Quick Ratio | 4.15x |
| Debt / Equity | 1.56x |
| Debt / EBITDA | 6.19x |
| Debt / FCF | 19.27x |
| Interest Coverage | 3.94x |
Returns and Efficiency
Return on invested capital is 6.99% over the last 12 months, against a 5-year average of 9.53%.
| Return on Equity (ROE) | 26.23% |
|---|---|
| Return on Assets (ROA) | 9.52% |
| Return on Invested Capital (ROIC) | 6.99% |
| Return on Capital Employed (ROCE) | 7.23% |
| ROE (5Y Average) | -9.40% |
| ROA (5Y Average) | -5.43% |
| ROIC (5Y Average) | 9.53% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 5.35x |
| Receivables Turnover | 6.64x |
| Cash Conversion Cycle | 109 days |
Scores
TMDX has an Altman Z-Score of 2.92, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.92 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $727.65M over the last 12 months.
| Revenue | $727.65M |
|---|---|
| Revenue Growth (YoY) | +28.48% |
| Gross Profit | $426.43M |
| Operating Income | $86.45M |
| Pretax Income | $73.62M |
| Net Income | $144.45M |
| EBITDA | $139.06M |
| EBIT | $98.64M |
| Reported EPS (TTM) | $1.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 36.23% of the $1.52B in total assets.
| Cash and Equivalents | $492.96M |
|---|---|
| Total Debt | $861.35M |
| Net Debt | $368.38M |
| Net Debt Per Share | $10.62 |
| Working Capital | $539.60M |
| Shareholder Equity | $550.71M |
| Book Value Per Share | $15.87 |
| Tangible Book Value | $529.88M |
| Tangible Book Per Share | $15.27 |
| Total Assets | $1.52B |
| Total Liabilities | $967.23M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $67.66M of capital spending, operating cash flow left $44.70M of free cash flow.
| Operating Cash Flow | $112.36M |
|---|---|
| Capital Expenditures | $67.66M |
| Free Cash Flow | $44.70M |
| FCF Per Share | $1.29 |
| Depreciation and Amortization | $40.41M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 11.88%, against a 5-year average of -29.88%.
| Gross Margin | 58.60% |
|---|---|
| Operating Margin | 11.88% |
| Pretax Margin | 10.12% |
| Net Margin | 19.85% |
| EBITDA Margin | 19.11% |
| EBIT Margin | 13.56% |
| FCF Margin | 6.14% |
| Gross Margin (5Y Average) | 64.56% |
| Operating Margin (5Y Average) | -29.88% |
| Net Margin (5Y Average) | -31.15% |
Growth
Revenue grew 86.42% a year over 3 years.
| Revenue Growth (3Y CAGR) | +86.42% |
|---|---|
| Revenue Growth (5Y CAGR) | +88.21% |
| Book Value Per Share Growth (2Y CAGR) | +69.69% |
| Tangible Book Per Share Growth (2Y CAGR) | +76.75% |
Dividends and Yields
TMDX does not pay a dividend. Its free cash flow yield is 1.37%.
| Earnings Yield | 1.39% |
|---|---|
| FCF Yield | 1.37% |
| Buyback Yield | -0.12% |
| Shareholder Yield | -0.12% |
Peer Position
Against 9 similar companies, TMDX has the 2nd highest P/E and the 3rd highest ROIC.
P/E RatioPeer median 23.6x
P/S RatioPeer median 3.2x
ROICPeer median 4.74%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.73%
| P/E Ratio | 72.2x vs 23.6x median |
|---|---|
| P/S Ratio | 4.5x vs 3.2x median |
| ROIC | 6.99% vs 4.74% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +28.48% vs +7.73% median |
Analyst Forecast
Consensus estimates put revenue growth at 22.01% and EPS growth at 3.27% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +22.01% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +3.27% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TMDX
What is TMDX's market cap?
TransMedics Group has a market cap of $3.20B. Its enterprise value, which adds debt and subtracts cash, is $3.57B.
What is TMDX's P/E ratio?
TransMedics Group has a trailing P/E ratio of 72.2x and a forward P/E of 55.0x.
How many shares of TMDX are outstanding?
TransMedics Group has 34.69M shares outstanding. The count is up 1.70% from a year earlier.
Does TMDX pay a dividend?
No. TransMedics Group does not pay a dividend.
How much debt does TMDX have?
TransMedics Group has $861.35M of total debt and $492.96M of cash and equivalents, a net debt position of $368.38M.
TMDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors